PrescribeToPrevent

Prescribe Naloxone, Save a Life

  • Clinician Resource
    • General
    • Emergency Medicine
    • Substance Use Disorder Treatment
  • OTC Naloxone
  • Patient Education
    • Videos
    • Online Training
    • Materials
  • Policy Resources
    • Research
    • Legal
    • Position Statements
  • FAQ
  • Contact Us

Pubmed April 2012 Update

Posted on 04.19.12 by p2p2015

Here we go with April 2012 …

Mortality and causes of death among users of methadone maintenance treatment in Israel, 1999-2008.
Rosca P, Haklai Z, Goldberger N, Zohar P, Margolis A, Ponizovsky AM.
Drug Alcohol Depend. 2012 Apr 6. [Epub ahead of print] Comment: Rate of overdose mortality was 0.22/100 person-years (i.e. 0.22%), one-quarter to one-fifth the expected rate in most studies of other cohorts

Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose.
Yokell MA, Zaller ND, Green TC, McKenzie M, Rich JD.
J Opioid Manag. 2012 Jan-Feb;8(1):63-6.
Comment: Buprenorphine is a partial agonist with a ceiling effect that limits the capacity for overdose among those with a tolerance to opioids. Like naloxone, buprenorphine really likes binding to opioid receptors and kicks most other opioids out. Since buprenorphine out-competes other opioids for receptors and has a ceiling effect, administration in the setting of overdose may result in reversal of opioid overdose. That said, this wouldn’t be the approach I would advocate for dissemination since (1) buprenorphine could cause overdose in an opioid user with minimal tolerance and (2) buprenorphine could cause prolonged withdrawal (for over a day) in those with a very high tolerance.

Understanding drug-related mortality in released prisoners: A review of national coronial records.
Andrews JY, Kinner SA.
BMC Public Health. 2012 Apr 4;12(1):270. [Epub ahead of print] Comment: An interesting exploration of circumstances surrounding prisoner death post-release.

Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide.
Goli V, Webster LR, Lamson MJ, Cleveland JM, Sommerville KW, Carter E.
Harm Reduct J. 2012 Mar 15;9(1):13. [Epub ahead of print] Comment: An intriguing analysis of whether or not injecting the pre-formulated morphine + naltrexone actually blocks the effects of morphine. It appears to partially, but not completely, block the effect.

Incidence and risk factors for non-fatal overdose among a cohort of recently incarcerated illicit drug users.
Kinner SA, Milloy MJ, Wood E, Qi J, Zhang R, Kerr T.
Addict Behav. 2012 Feb 7. [Epub ahead of print] Comment: Prior overdose, daily or binge drug use, and public injecting are associated with nonfatal overdose among recently released drug users.

Dexmedetomidine infusion to facilitate opioid detoxification and withdrawal in a patient with chronic opioid abuse.
Upadhyay SP, Mallick PN, Elmatite WM, Jagia M, Taqi S.
Indian J Palliat Care. 2011 Sep;17(3):251-4.
Comment: An interesting use of a particular sedative to assist with opioid withdrawal in an intensive care unit.

Drug-related deaths with evidence of intracorporeal drug concealment at autopsy: five case reports.
Wilcher G.
Am J Forensic Med Pathol. 2011 Dec;32(4):314-8.
Comment: Intriguing review of 5 cases of drug-induced death among “body packers” or “body stuffers”, including a review of that language. Interestingly, most of the deaths were due to overdose on consumed drugs rather than toxicity from rupture of drug packets.

Categories: Buprenorphine, Methadone, naltrexone, prisoners, Pubmed, PubMed Update, Research Brief

Previous update: Pubmed March 2012 Update
Next update: Pubmed May 2012 Update

Comments

  1. Dan Bigg says

    April 19, 2012 at 6:13 am

    Phillip – Thanks again for keeping your keen eye on the lit and translating it for us lay — read 'too lazy' –folk… Peace, Dan

  2. Phillip Coffin says

    April 21, 2012 at 4:43 am

    my pleasure – hope it is useful.

Search for research content: author, keyword, etc…

PubMed Update Archives

  • April 2021
  • January 2021
  • April 2020
  • February 2020
  • January 2020
  • April 2019
  • February 2019
  • December 2018
  • September 2018
  • August 2018
  • March 2018
  • January 2018
  • November 2017
  • September 2017
  • June 2017
  • January 2017
  • November 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • May 2015
  • March 2015
  • November 2014
  • August 2014
  • July 2014
  • May 2014
  • March 2014
  • February 2014
  • January 2014
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • February 2013
  • December 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • June 2011
  • May 2011

prescribetoprevent@gmail.com

site by: web360

  • Clinician Resource
    • General
    • Emergency Medicine
    • Substance Use Disorder Treatment
  • OTC Naloxone
  • Patient Education
    • Videos
    • Online Training
    • Materials
  • Policy Resources
    • Research
    • Legal
    • Position Statements
  • FAQ

Copyright 2022 PrescribeToPrevent.org